DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/dplkjg/idiopathic_thrombo) has announced the addition of GlobalData 's new report "Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global ITP therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ITP therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Idiopathic Thrombocytopenic Purpura Therapeutics Market is Forecast to Show Moderate Growth until 2019
GlobalData's analysis estimated the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market was worth $299.06m in 2011. It is forecast to show moderate growth at a Compound Annual Growth Rate (CAGR) of 5.38% for the next eight years to reach $454.95m by 2019. The market witnessed significant growth during 2006-2011 owing to the launch of Nplate (romiplostim) in 2008 in the US and in Europe in 2009. In addition to this, Promacta/Revolade (eltrombopag) was launched in the US in 2009 and in Europe in 2010. The moderate growth in the ITP therapeutics market can be attributed to the strong performance of the both of these products during the forecast period. The expected launch of IGIV3I 10% Grifols will also contribute to the growth of the market during the forecast period.
Companies Mentioned
- F. Hoffmann-La Roche
- Grifols Biologicals Inc.
- Amgen Inc.
- GlaxoSmithKline plc
For more information visit http://www.researchandmarkets.com/research/dplkjg/idiopathic_thrombo
Source: GlobalData